A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics